Improved MSC Minimal Criteria to Maximize Patient Safety: A Call to Embrace Tissue Factor and Hemocompatibility Assessment of MSC Products

Abstract The number of mesenchymal stromal/stem cell (MSC) therapeutics and types of clinical applications have greatly diversified during the past decade, including rapid growth of poorly regulated “Stem Cell Clinics” offering diverse “Unproven Stem Cell Interventions.” This product diversification...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Stem cells translational medicine Ročník 11; číslo 1; s. 2 - 13
Hlavní autori:	Moll, Guido, Ankrum, James A, Olson, Scott D, Nolta, Jan A
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	US Oxford University Press 03.03.2022
Predmet:	Blood Coagulation Case reports Clinical trials Humans Mesenchymal Stem Cell Transplantation - adverse effects Mesenchymal Stem Cells - metabolism Patient safety Stem cells Therapeutic applications Thromboembolism Thromboplastin - metabolism Tissue factor mesenchymal stromal/stem cells (MSCs) product diversification hemocompatibility thromboembolism safety and efficacy coagulopathy cellular therapy tissue source coagulation tissue factor/CD142/Factor III/F3
ISSN:	2157-6564, 2157-6580, 2157-6580
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!